TEB-17231

提醒：本报告使用AI深度研究能力，请谨慎参考，不能作为诊疗意见。 胰腺导管腺癌（PDAC）是全球预后最差的实体恶性肿瘤之一，五年生存率长期低于10%[117][1][268][2]。尽管KRAS基因突变是该疾病最常见的驱动事件，存在于约90%的病例中，但仍有约5-10%的患者携带KRAS野生型（wild-type, WT）肿瘤[268][3][356][4]。 这一亚群的分子特征、临床预后和治疗选择与KRAS突变型患者存在显著差异。 近年来，随着泛KRAS抑制剂和泛RAS抑制剂的突破性进展，针对KRAS野生型患者的精准治疗策略正从理论走向临床实践，但其中涉及的分子机制复杂性、药物选择性原理、检测标准化要求以及治疗决策框架仍需系统梳理和深入理解。 本报告旨在全面解析KRAS野生型胰腺癌患者在接受RAS靶向治疗时的关键科学问题，包括野生型靶向的分子障碍、临床试验入选条件的生物学依据、检测策略的技术路径，以及从标准治疗到个性化精准医疗的完整临床管理方案。❤️欢迎加入社区KRAS-WT专题社群 交流信息，相互鼓励，欢迎野生型KRAS病友/家属申请加入。 添加管理员微信号: Pruchen(需要提交野生型基因检测报告)RAS/MAPK信号通路与KRAS突变的分子基础 RAS蛋白家族（KRAS、NRAS、HRAS）作为小GTP酶，在细胞信号转导中扮演着分子开关的核心角色。这些蛋白通过在其活性GTP结合状态（RAS-GTP，即"ON"状态）与非活性GDP结合状态（RAS-GDP，即"OFF"状态）之间循环，精确调控下游MAPK和PI3K-AKT-mTOR等关键信号通路的活性[42][5][266][6]。在正常细胞中，这一循环受到鸟嘌呤核苷酸交换因子（GEFs，如SOS1/2）和GTP酶激活蛋白（GAPs，如NF1）的严格调控，确保细胞增殖、分化和存活信号的适度和可控。 KRAS蛋白的致癌转化主要源于点突变导致的GTP酶活性丧失。在胰腺导管腺癌中，最常见的突变位点位于12号密码子，其中G12D（约35%）、G12V（20-30%）和G12R（10-20%）占据主导地位[268][7][336][8]。 这些突变通过不同的分子机制破坏KRAS的GTP水解能力，使蛋白持续滞留于GTP结合的活性状态，导致下游信号通路的组成性激活。具体而言，G12C突变引入了一个反应性半胱氨酸残基，为共价抑制剂的设计提供了独特的药理学靶点；而G12D和G12V突变则主要通过空间位阻效应干扰GAP介导的GTP水解[204][9][247][10]。 值得注意的是，不同突变亚型在PDAC中的分布和预后意义存在显著差异，G12R突变通常与相对较好的预后相关，而G12D突变则与更具侵袭性的疾病表型相关[268][11][305][12]。 KRAS野生型肿瘤虽然缺乏经典的热点突变，但其生物学行为和对治疗的反应性呈现高度异质性。从功能角度分析，野生型KRAS蛋白仍保留正常的GTPase活性，能够响应上游受体酪氨酸激酶（RTK）的信号输入，并在适当条件下激活下游效应通路[41][13][42][14]。 这一特征既是野生型肿瘤维持恶性表型的基础，也为靶向治疗带来了独特的挑战和机遇。研究表明，KRAS野生型PDAC患者通常具有更长的总生存期（中位OS 38个月 vs 22个月），且更可能携带其他可靶向的基因组改变，包括BRAF突变、NRG1融合、NTRK融合、MSI-H/dMMR状态以及HER2扩增等[268][15][356][16]。 这种分子特征的多样性使得KRAS野生型PDAC成为一个需要高度个体化评估和治疗的独特临床亚群。KRAS抑制剂的技术演进与野生型靶向困境 KRAS长期以来被认为是"不可成药"的靶点，这主要源于其蛋白结构的固有特征。作为GTP酶，KRAS对天然底物GTP具有皮摩尔级别的高亲和力，且细胞内GTP浓度处于毫摩尔水平，使得竞争性核苷酸类似物抑制剂的开发极为困难[17][17][19][18]。此外，KRAS蛋白表面光滑，缺乏适合小分子药物结合的经典深疏水口袋，进一步增加了靶向开发的挑战性[8][19][244][20]。然而，2013年Shokat实验室在KRAS(G12C)突变体的Switch-II区域发现了一个可诱导的变构口袋（S-IIP），这一发现彻底改变了KRAS靶向治疗的格局[247][21]。 第一代KRAS抑制剂主要针对G12C突变体的GDP结合状态（"OFF"状态）。这类抑制剂通过与突变引入的半胱氨酸残基形成共价键，不可逆地将KRAS(G12C)锁定在非活性构象，从而阻断下游信号传导[1][22][19][23][87][24]。Sotorasib（AMG 510）和Adagrasib（MRTX849）是这一类药物的代表，它们已在KRAS G12C突变的非小细胞肺癌中获得FDA批准，并在PDAC中显示出临床活性[268][25][326][26]。在CodeBreaK 100试验中，Sotorasib在38例既往接受过治疗的KRAS G12C突变PDAC患者中实现了21%的客观缓解率（ORR），中位无进展生存期（mPFS）为4.0个月，中位总生存期（mOS）为6.9个月[325][27][326][28]。KRYSTAL-1试验则显示Adagrasib的ORR达到33.3%，mPFS为5.6个月，mOS为8个月[268][29]。这些数据证明了直接靶向KRAS的可行性，但也暴露出一个关键问题：这类抑制剂的疗效受限于它们仅能靶向GDP结合的"OFF"状态，而KRAS G12C蛋白在细胞内主要以GTP结合的"ON"状态存在。 对于KRAS野生型患者而言，靶向治疗的困境更为复杂。野生型KRAS蛋白缺乏G12C突变特有的反应性半胱氨酸残基，使得共价抑制剂无法与之结合[204][30]。更为关键的是，野生型蛋白维持正常的GTPase循环，在"ON"和"OFF"状态之间动态转换，而传统的"OFF"状态抑制剂只能结合GDP结合构象，无法有效阻断处于GTP结合活性状态的野生型KRAS信号[267][31][312][32]。此外，野生型KRAS在多种正常组织中广泛表达并具有重要的生理功能，这增加了全身性抑制野生型KRAS可能带来的毒性风险。 近期发展的Switch-II口袋非共价抑制剂和**三元复合物抑制剂（Tri-Complex Inhibitors, TCIs）**为解决上述困境提供了新的策略。非共价Switch-II口袋抑制剂（如BI-2493和BI-2865）能够可逆地结合KRAS的Switch-II区域，阻断效应蛋白（如RAF）的结合，且这种结合不依赖于特定突变残基的存在[312][33]。 然而，这类抑制剂主要针对GDP结合的"OFF"状态，对于高度激活的野生型KRAS的抑制效果有限。相比之下，三元复合物抑制剂代表了一种革命性的新机制。以RMC-6236（daraxonrasib）为代表的TCIs通过与亲环素A（Cyclophilin A, CypA）形成二元复合物，再以分子胶的方式结合活性GTP结合状态的RAS蛋白，形成稳定的三元复合物（CypA-药物-RAS），从而阻断RAS与下游效应蛋白的相互作用[266][34][182][35]。 这种机制的独特优势在于能够靶向"ON"状态的RAS，无论其是突变型还是野生型，且对KRAS、NRAS和HRAS三种亚型均具有活性。在RASolute 302等三期临床试验中，RMC-6236在既往接受过治疗的转移性PDAC患者中显示出令人鼓舞的抗肿瘤活性和生存获益[336][36][338][37][342][38]，并于2025年7月获得FDA突破性疗法认定。 另一个重要的机制考量是上游信号通路的反馈激活。研究表明，当使用KRAS抑制剂阻断突变型KRAS信号时，细胞会通过受体酪氨酸激酶（RTK，主要是EGFR）介导的机制代偿性激活野生型NRAS、HRAS甚至KRAS，从而维持MAPK通路的持续激活，导致治疗耐药[42][39][43][40][271][41][272][42]。Ryan等人的研究明确指出，这种"KRAS(G12C)-非依赖性的野生型RAS反馈激活"是限制KRAS(G12C)抑制剂疗效的关键机制，而非简单的G12C向GTP状态转换[43][43][52][44]。对于KRAS野生型扩增的肿瘤而言，上游RTK信号对野生型KRAS的激活可能直接驱动肿瘤生长，这使得单纯抑制突变型KRAS（在不存在突变的情况下）或靶向野生型KRAS本身的策略面临更复杂的调控网络挑战**。KRAS野生型扩增的生物学基础与临床入选阈值 在KRAS野生型肿瘤中，基因拷贝数扩增（copy number amplification, CNA）代表了一种独特的致癌驱动机制，与传统的点突变具有本质不同的生物学特征。拷贝数扩增通过增加野生型等位基因的剂量，导致KRAS蛋白表达水平升高，进而增强下游信号通路的基线活性，最终驱动肿瘤的发生和进展[85][45][205][46][354][47]。这一机制的有效性已在多种实体瘤中得到验证，包括胃食管癌、结直肠癌和非小细胞肺癌[173][48]。 基因剂量效应与蛋白表达阈值是理解KRAS野生型扩增对抑制剂敏感性的核心。2025年发表于Molecular Cancer Therapeutics的研究基于Broad Institute的PRISM高通量药物筛选平台和TCGA数据库分析，系统性地评估了KRAS野生型拷贝数与泛KRAS抑制剂敏感性的关系[205][49]。该研究发现，随着KRAS相对拷贝数的增加，肿瘤细胞对BI-2493和BI-2865等Switch-II口袋抑制剂的敏感性呈现剂量依赖性增强。统计学分析显示，当KRAS相对拷贝数超过7时，这种敏感性提升具有统计学显著性（Wilcoxon P值=0.014）。更关键的是，研究人员观察到当KRAS相对拷贝数达到7时，细胞中KRAS蛋白的表达水平出现急剧升高的拐点，提示存在一个与致癌转化相关的蛋白表达阈值。 从分子机制角度分析，KRAS野生型扩增对Switch-II口袋抑制剂的敏感性源于蛋白池的扩大与GDP结合状态的富集。野生型KRAS蛋白在细胞内持续进行GTP-GDP循环，但相对于致癌突变体，其循环动力学更快，且大部分时间内处于GDP结合的"OFF"状态[312][50]。当KRAS基因拷贝数显著增加时，细胞质中KRAS蛋白的总量相应升高，导致GDP结合形式的野生型KRAS绝对数量大幅增加。Switch-II口袋抑制剂（如BGB-53038、BI-2493、BI-2865）通过与GDP结合状态的KRAS结合，将其锁定在非活性构象，从而有效降低可用于信号转导的功能性KRAS蛋白总量[312][51]。在高拷贝数背景下，这种抑制作用足以阻断维持细胞存活和增殖所需的RAS信号输出，达到与直接抑制致癌突变体相当的治疗效果。KRAS野生型扩增和阈值说明 CN≥8阈值的确立基于多维度数据的综合分析。研究团队首先通过PRISM平台筛选了数百种细胞系，发现相对拷贝数>7（即≥8）的细胞系对泛KRAS抑制剂表现出最显著的敏感性。随后，TCGA队列的生存分析证实，KRAS相对拷贝数>7的患者临床预后显著更差，分层Cox回归分析显示该阈值分组具有统计学显著性差异[205][52]。基于这些临床前和临床数据，相关药物开发者将KRAS野生型扩增的入选阈值设定为拷贝数≥8。例如，BGB-53038的首次人体临床试验（NCT06585488）明确纳入"KRAS野生型扩增（拷贝数≥8）"的患者群体[100][53][101][54]，而BI-2493/BI-2865的后续临床开发也聚焦于这一分子亚群[173][55]。 值得注意的是，KRAS拷贝数扩增的检测和定义在不同的检测平台和研究中存在差异。通常，拷贝数变异（CNV）的检测基于NGS或FISH技术，通过与正常二倍体参考基因组比较计算相对拷贝数。FoundationOne CDx等商业化的NGS panel通常将拷贝数≥8定义为高水平扩增[93][56][94][57]。在液体活检中，通过cfDNA检测KRAS拷贝数增加需要更高的灵敏度，因为ctDNA的丰度和片段化可能影响检测准确性[287][58][288][59]。此外，KRAS扩增常与野生型等位基因的保留共存，与突变型KRAS的拷贝数增加（mutant allele-specific imbalance）是不同的生物学现象，后者涉及突变等位基因的优先扩增[178][60][307][61][351][62]。 与BGB-53038等pan-KRAS抑制剂不同，YL-17231和GFH276等pan-RAS抑制剂在KRAS野生型患者中的入选逻辑更为复杂。 YL-17231是一种口服小分子pan-RAS抑制剂，其临床试验（NCT06096974）纳入的是"携带KRAS、NRAS或HRAS突变的晚期实体瘤患者"[154][63][155][64]。然而，根据280Bio的AACR 2023摘要，YL-17231在KRAS扩增（KRAS ampl）的细胞系中同样显示出强效抑制活性，KURAMOCHI细胞系（KRAS ampl）的IC50为12.4 nM[265][65]。这表明YL-17231可能对KRAS野生型扩增患者有效，但其正式临床试验并未明确开放KRAS野生型扩增队列，除非同时存在其他RAS突变[196][66]。 GFH276则采用了不同的机制——作为molecular glue panRAS(ON)抑制剂，它通过三元复合物机制靶向GTP结合的活性状态RAS，且在临床前研究中显示出对上游RTK激活诱导的耐药不敏感的特性[311][67]。这种机制上的独特性可能使其在特定分子背景（如RTK改变伴随的RAS通路激活）下的KRAS野生型肿瘤中具有应用潜力，但截至目前，GFH276的临床试验主要聚焦于携带RAS突变的患者群体[208][68][212][69]。针对KRAS野生型患者的检测策略与分子分型 对KRAS野生型胰腺导管腺癌患者实施精准治疗的前提是通过系统性的分子检测识别可靶向的基因组改变。2025年的ESMO和NCCN指南均强烈推荐对所有晚期/转移性PDAC患者进行肿瘤NGS检测，以识别罕见的但具有临床意义的治疗靶点[207][70][279][71][282][72]。对于KRAS野生型患者，这一检测尤为关键，因为该群体富集了多种可靶向的分子改变。 **综合基因组分析（Comprehensive Genomic Profiling, CGP）**应采用DNA和RNA联合检测的策略[314][73][320][74]。DNA-based NGS主要用于检测单核苷酸变异（SNVs）、小片段插入缺失（indels）和拷贝数变异（CNVs），而RNA测序对于识别基因融合（如NRG1、NTRK、FGFR2、ALK、RET融合）至关重要，因为许多融合事件发生在内含子区域或涉及复杂的基因组重排，仅通过DNA测序可能漏检[207][75][356][76]。一项纳入785例PDAC患者的研究发现，9%的病例为KRAS野生型，其中43.8%存在可靶向的MAPK通路驱动改变[207][77]。另一项基于FoundationOne数据库的大规模分析显示，在721例KRAS野生型PDAC中，ERBB2（6.8%）、BRAF（17.9%）、PIK3CA（6.5%）、FGFR2（4.4%）和ATM（6.8%）的突变频率显著高于KRAS突变型肿瘤[357][78]。 KRAS状态的确证是检测流程的第一步。通过NGS panel检测KRAS基因2号外显子（主要是12、13号密码子）和3号外显子（61号密码子）的突变状态，可以明确区分KRAS突变型和野生型肿瘤。对于KRAS野生型病例，需要进一步评估KRAS拷贝数状态。基于NGS的CNV分析通过与参考基因组比较计算基因的相对拷贝数，通常使用对数比值（log2 ratio）或归一化拷贝数来表示。如前文所述，KRAS野生型扩增的临界值通常设定为拷贝数≥8（或相对拷贝数>7），这一阈值与泛KRAS抑制剂的敏感性相关[100][79][205][80]。在临床实践中，需要使用经过验证的商业化NGS平台（如FoundationOne CDx、MSK-IMPACT）或符合CLIA/CAP标准的实验室自建方法进行检测。 **液体活检（Liquid Biopsy）**通过检测循环肿瘤DNA（ctDNA）为组织活检提供了重要的补充手段。ctDNA分析可以克服肿瘤异质性和组织获取困难的问题，特别适用于无法获取足够肿瘤组织或需要动态监测的患者[287][81][297][82]。对于KRAS野生型扩增的检测，ddPCR（数字PCR）和NGS-based液体活检方法均可以检测KRAS拷贝数增加[289][83][291][84]。一项研究评估了基于血浆cfDNA的KRAS拷贝数变异分析在胰腺癌诊断和预后中的价值，显示该方法具有可行性[287][85]。然而，液体活检的灵敏度受限于ctDNA的释放量和检测平台的分析灵敏度，通常需要突变等位基因频率（MAF）达到1-2%以上才能可靠检测[288][86][292][87]。 除了KRAS状态本身，KRAS野生型PDAC患者还需要进行扩展分子分型以识别其他治疗靶点： 可靶向改变在KRAS野生型PDAC中的发生率推荐检测方法对应治疗策略BRAF V600E突变约18% [357][88]DNA NGS达拉非尼+曲美替尼（已获批用于实体瘤）[268][89]NRG1融合约6-10%（在KRAS野生型中） [207][90][356][91]RNA-seq/DNA NGS（含内含子覆盖）Zenocutuzumab（HER2×HER3双特异性抗体，ORR 42%）[207][92]NTRK1/2/3融合<1%（PDAC总体），但在KRAS野生型中富集 [207][93]RNA-seq/IHCLarotrectinib、Entrectinib（已获批）[268][94]MSI-H/dMMR约2-5%（在KRAS野生型中更高） [130][95][268][96]IHC/MSI-PCR/NGS TMBPembrolizumab（已获批）[268][97]HER2扩增/过表达约2-7% [207][98][357][99]IHC/ISH/DNA NGSTrastuzumab deruxtecan（临床试验中）[357][100]RET融合罕见 [222][101]RNA-seqSelpercatinib、Pralsetinib（已获批）[268][102]BRCA1/2/PALB2突变约3-5%（胚系） [268][103]胚系+体细胞NGS奥拉帕利维持治疗（已获批）[268][104]FGFR2融合/突变约4% [357][105]RNA-seq/DNA NGSErdafitinib（个案报道有效）[357][106]ALK融合罕见 [356][107]RNA-seq/DNA NGS克唑替尼、阿来替尼（已获批）[222][108] 上述数据显示，KRAS野生型PDAC具有高度异质性的分子景观，约40-50%的病例携带至少一种可靶向的基因组改变[207][109][356][110]。因此，系统性的分子检测不仅有助于识别适合参加特定临床试验（如BGB-53038的KRAS野生型扩增队列）的患者，更能够指导标准的靶向治疗决策，实现真正的精准医疗。KRAS野生型胰腺癌的治疗策略与临床路径 对于KRAS野生型胰腺导管腺癌患者，治疗决策应基于疾病分期、分子特征和患者整体状况进行综合考量。与KRAS突变型患者相比，野生型患者通常具有更好的总体预后（中位OS 38个月 vs 22个月）[268][111]，且更可能从靶向治疗中获益，这使得分子分型指导的个体化治疗策略尤为重要。 一线标准治疗目前仍以系统性化疗为主。根据2025年NCCN和ESMO指南，FOLFIRINOX（氟尿嘧啶、亚叶酸钙、伊立替康、奥沙利铂）和吉西他滨联合白蛋白结合型紫杉醇（Gem/Nab-Pac）是转移性PDAC的推荐一线方案[117][112]。一项针对转移性PDAC的研究显示，无论KRAS突变状态如何，FOLFIRINOX治疗均能带来最长的中位总生存期（12.2个月）[128][113]。然而，对于KRAS野生型患者，特别是携带可靶向基因组改变（如BRAF突变、NRG1融合、MSI-H）的病例，应优先考虑靶向治疗或参加相应的临床试验。一项回顾性分析显示，在接受分子分型指导的匹配治疗的PDAC患者中，中位总生存期显著长于未匹配治疗的患者（2.58年 vs 1.51年）[207][114]。 针对特定可靶向改变的精准治疗已在KRAS野生型PDAC中显示出明确的临床活性。对于携带BRAF V600E突变的患者，达拉非尼联合曲美替尼的双重靶向方案基于ROAR篮子研究和NCI-MATCH试验的数据已获得FDA批准用于BRAF V600E突变的实体瘤[268][115]。BRAF突变在KRAS野生型PDAC中的发生率约为18%，显著高于KRAS突变型（0.5%）[357][116]。NRG1融合是另一个重要的可靶向改变，在KRAS野生型PDAC中相对少见（约1-2%）[207][117]，患者通常较年轻（中位诊断年龄48.5岁）[207][118]。Zenocutuzumab是一种ADCC增强的双特异性抗HER2/HER3抗体，能够阻断NRG1-beta与HER3的结合，从而抑制下游信号传导。在NRG1融合阳性的PDAC患者中，zenocutuzumab显示出42%的客观缓解率（基于包含158例NRG1+晚期肿瘤患者的II期试验，其中PDAC亚组占21%），中位缓解持续时间为11.1个月[207][119]。此外，MSI-H/dMMR状态的PDAC患者（在总体PDAC中约占1-3%，在KRAS野生型中比例可能更高）对免疫检查点抑制剂帕博利珠单抗反应良好，这在KEYNOTE-158等试验中得到证实[268][120]。NTRK融合虽然罕见，但larotrectinib和entrectinib等TRK抑制剂在携带该融合的PDAC患者中已显示出持久的抗肿瘤活性[207][121]。 新兴KRAS抑制剂的临床试验机会为KRAS野生型扩增患者提供了新的治疗选择。BGB-53038是百济神州开发的口服pan-KRAS抑制剂，其首次人体临床试验（NCT06585488）明确纳入KRAS野生型扩增（拷贝数≥8）的晚期实体瘤患者[100][122][101][123][204][124]。该药物作为pan-KRAS抑制剂，可阻断KRAS依赖性信号传导，对多种KRAS突变形式和野生型扩增均具有抑制活性[204][125]。此外，RMC-6236（daraxonrasib）作为RAS(ON)多选择性三元复合物抑制剂，其在PDAC中的临床开发已取得重大进展。RMC-6236通过结合亲环素A形成二元复合物，再与GTP结合的活性状态RAS（包括KRAS、NRAS、HRAS的突变型和野生型）形成三元复合物，从而阻断RAS信号传导[266][126][182][127]。在RASolute 302等三期临床试验中，RMC-6236在既往接受过治疗的转移性PDAC患者中显示出令人鼓舞的抗肿瘤活性和生存获益[336][128][338][129]，并于2025年7月获得FDA突破性疗法认定[342][130]。虽然RMC-6236的主要开发焦点是KRAS突变型PDAC，但其靶向活性状态RAS的机制理论上对KRAS野生型扩增（注意：是扩增定义）的肿瘤同样有效，这为未来的临床应用提供了可能性。 二线及后续治疗的选择应基于一线治疗的反应、疾病进展模式和分子检测结果进行个体化调整。对于在一线治疗期间或之后出现疾病进展的KRAS野生型患者，如果此前未接受过靶向治疗且分子检测识别出可靶向改变，应优先考虑相应的靶向治疗。对于不适合靶向治疗或靶向治疗失败的患者，二线化疗方案（如脂质体伊立替康联合5-氟尿嘧啶/亚叶酸钙）仍是重要的选择[268][131]。此外，参加针对新型KRAS抑制剂、泛RAS抑制剂或其他创新机制的临床试验应为标准临床实践的一部分，特别是在标准治疗方案失败后[268][132]。结论与展望 KRAS野生型胰腺导管腺癌作为一个独特的分子亚群，其精准治疗的实现依赖于对分子机制的深入理解、系统性的分子检测以及个体化的治疗决策。 从机制角度，传统KRAS抑制剂难以靶向野生型蛋白的结构性障碍（缺乏共价结合位点、GTP/GDP动态循环）已被新型作用机制所克服，包括Switch-II口袋非共价抑制剂和三元复合物抑制剂。特别是针对KRAS野生型扩增（CN≥8）的肿瘤，泛KRAS抑制剂通过结合大量存在的GDP结合状态蛋白，能够有效阻断致癌信号传导。 从检测角度，DNA和RNA联合NGS panel是识别KRAS状态、拷贝数变异和其他可靶向改变的基石，液体活检作为补充手段在特定临床场景下具有重要价值。从治疗角度，KRAS野生型患者不仅应接受标准的系统性化疗，更应积极寻求分子分型指导的靶向治疗机会，包括针对BRAF、NRG1、NTRK、MSI-H等改变的已获批疗法，以及针对KRAS野生型扩增的临床试验（如BGB-53038）。 未来的研究方向应聚焦于以下几个关键领域： 首先，需要进一步明确KRAS野生型扩增在不同癌种中的发生率和对RAS抑制剂的敏感性谱系，以优化患者筛选策略； 其次，三元复合物抑制剂等新型RAS抑制剂的临床开发应探索其在KRAS野生型扩增肿瘤中的活性； 第三，联合治疗策略（如RAS抑制剂联合RTK抑制剂、RAS抑制剂联合免疫治疗）的开发可能克服单一靶点抑制的局限性； 最后，基于液体活检的动态监测和耐药机制研究将为治疗策略的实时调整提供依据。 随着对RAS生物学理解的不断深入和新药研发技术的持续进步，KRAS野生型胰腺癌患者的治疗前景正在显著改善，精准医疗的理念正逐步转化为现实的临床获益。 一起加油，㊗️顺利！参考资料 1. KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance[133] - [1][134] 2. KRAS G12C Game of Thrones, which direct KRAS inhibitor will ...[135] - [8][136] 3. Nucleotide based covalent inhibitors of KRas can only be ...[137] - [17][138] 4. Targeting KRAS G12C: from inhibitory mechanism to ... - PMC[139] - [19][140] 5. Wild-type RAS signaling is an essential therapeutic target in ... - PMC[141] - [41][142] 6. Concurrent inhibition of oncogenic and wild-type RAS-GTP ... - Nature[143] - [42][144] 7. KRASG12C-independent feedback activation of wild-type RAS ...[145] - [43][146] 8. KRAS G12C-independent feedback activation of wild-type ...[147] - [52][148] 9. Clinicogenomic landscape of pancreatic adenocarcinoma identifies ...[149] - [85][150] 10. Identification of the Clinical Development Candidate MRTX849, a ...[151] - [87][152] 11. Page 1 of 110 FoundationOne®CDx Technical Information ...[153] - [93][154] 12. Bioinformatically-expanded next-generation sequencing ...[155] - [94][156] 13. NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS ...[157] - [100][158] 14. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone ...[159] - [101][160] 15. Systemic Therapy for Advanced Pancreatic Cancer in 2025[161] - [117][162] 16. KRAS Mutation Status and Outcomes in Metastatic Pancreatic ...[163] - [128][164] 17. KRAS wild-type pancreatic ductal adenocarcinoma - PMC - NIH[165] - [130][166] 18. Study Details | NCT06096974 | Pan-RAS Inhibitor YL-17231 in ...[167] - [154][168] 19. Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid ...[169] - [155][170] 20. Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor ...[171] - [173][172] 21. Multiomic quantification of the KRAS mutation dosage improves the ...[173] - [178][174] 22. Translational and Therapeutic Evaluation of RAS-GTP ...[175] - [182][176] 23. ClinicalTrials.gov[177] - [196][178] 24. Definition of pan-KRAS inhibitor BGB-53038 - NCI Drug Dictionary - NCI[179] - [204][180] 25. Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification | Molecular Cancer Therapeutics | American Association for Cancer Research[181] - [205][182] 26. Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard‐of‐Care and Emerging Therapeutic Strategies - Kwok - Journal of Gastroenterology and Hepatology - Wiley Online Library[183] - [207][184] 27. GenFleet Therapeutics Announces First Patient Dosed with GFH276 ...[185] - [208][186] 28. GenFleet Therapeutics Inc. Announces First Patient Dosed in A ...[187] - [212][188] 29. Pancreatic cancer in 2025: Have we found a solution?[189] - [222][190] 30. Biophysical and structural analysis of KRAS switch-II pocket ...[191] - [244][192] 31. Fragment Optimization of Reversible Binding to the Switch II Pocket ...[193] - [247][194] 32. https%3A%2F%2F280bio.com%2Fwp-content%2Fuploads%2F2023%2F04%2F2627_AACR-TEB-17231-sized.pdf[195] - [265][196] 33. https%3A%2F%2Fwww.revmed.com%2Fwp-content%2Fuploads%2F2024%2F04%2FAACR2024_6236_FINAL-DRAFT.pdf[197] - [266][198] 34. Ras Binder Induces a Modified Switch-II Pocket in GTP- and GDP-States - PMC[199] - [267][200] 35. Actionable mutations in pancreatic cancer: where targeted therapies are making a difference - PMC[201] - [268][202] 36. KRASG12C-independent feedback activation of wild-type RAS ...[203] - [271][204] 37. Vertical Pathway Inhibition Overcomes Adaptive Feedback ...[205] - [272][206] 38. Germline Testing, Molecular Profiling Now Recommended in NCCN ...[207] - [279][208] 39. Pan-Asian adapted ESMO Clinical Practice Guidelines for the ...[209] - [282][210] 40. KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid ...[211] - [287][212] 41. Detection of KRAS mutations in liquid biopsies from metastatic ...[213] - [288][214] 42. Efficient and accurate KRAS genotyping using digital PCR ... - Nature[215] - [289][216] 43. Comparison of KRAS gene in circulating tumor DNA levels vs ... - PMC[217] - [291][218] 44. Identification of a Clinical Cutoff Value for Multiplex KRASG12/G13 ...[219] - [292][220] 45. ESMO recommendations on the use of circulating tumour DNA ...[221] - [297][222] 46. Distinct clinical outcomes and biological features of specific KRAS ...[223] - [305][224] 47. Elevated KRAS protein level is associated with better survival ...[225] - [307][226] 48. GFH276 / GenFleet Therap[227] - [311][228] 49. Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification | Molecular Cancer Therapeutics | American Association for Cancer Research[229] - [312][230] 50. The Role of DNA & RNA in Comprehensive Genomic ...[231] - [314][232] 51. NCCN Updates Pancreatic Cancer Guidelines ...[233] - [320][234] 52. Sotorasib shows clinically meaningful activity in KRAS G12C ...[235] - [325][236] 53. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer[237] - [326][238] 54. Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit ...[239] - [336][240] 55. Trial in progress: RASolute 302—A phase 3, multicenter, global ...[241] - [338][242] 56. Daraxonrasib Earns FDA Breakthrough Status in Pancreatic Cancer[243] - [342][244] 57. Increased mutant KRAS gene dosage drives pancreatic cancer ...[245] - [351][246] 58. Amplification of wild-type KRAS associates with elevated ...[247] - [354][248] 59. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma | Nature Communications[249] - [356][250] 60. Frontiers | Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma[251] - [357][252]引用链接 [1] [117]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[2] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[3] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[4] [356]: https://www.nature.com/articles/s41467-022-33718-7[5] [42]: https://www.nature.com/articles/s41586-024-07205-6[6] [266]: https://www.revmed.com/wp-content/uploads/2024/04/AACR2024_6236_FINAL-DRAFT.pdf[7] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[8] [336]: https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit[9] [204]: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-kras-inhibitor-bgb-53038[10] [247]: https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01120[11] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[12] [305]: https://www.cell.com/cancer-cell/fulltext/S1535-6108(24)00296-4[13] [41]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12983336/[14] [42]: https://www.nature.com/articles/s41586-024-07205-6[15] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[16] [356]: https://www.nature.com/articles/s41467-022-33718-7[17] [17]: https://www.nature.com/articles/s41598-017-03973-6[18] [19]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7669705/[19] [8]: https://www.sciencedirect.com/science/article/abs/pii/S0305737220300128[20] [244]: https://www.jbc.org/article/S0021-9258(25)02181-7/fulltext[21] [247]: https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01120[22] [1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11049385/[23] [19]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7669705/[24] [87]: https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02052[25] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[26] [326]: https://pubmed.ncbi.nlm.nih.gov/36546651/[27] [325]: https://www.mdanderson.org/newsroom/kras-inhibitor-sotorasib-shows-meaningful-activity-pancreatic-cancer.h00-159545268.html[28] [326]: https://pubmed.ncbi.nlm.nih.gov/36546651/[29] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[30] [204]: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-kras-inhibitor-bgb-53038[31] [267]: https://pmc.ncbi.nlm.nih.gov/articles/PMC5915340/[32] [312]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[33] [312]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[34] [266]: https://www.revmed.com/wp-content/uploads/2024/04/AACR2024_6236_FINAL-DRAFT.pdf[35] [182]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11149917/[36] [336]: https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit[37] [338]: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4230[38] [342]: https://www.targetedonc.com/view/daraxonrasib-earns-fda-breakthrough-status-in-pancreatic-cancer[39] [42]: https://www.nature.com/articles/s41586-024-07205-6[40] [43]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9809542/[41] [271]: https://www.researchgate.net/publication/361445890_KRASG12C-independent_feedback_activation_of_wild-type_RAS_constrains_KRASG12C_inhibitor_efficacy[42] [272]: https://aacrjournals.org/clincancerres/article/26/7/1633/265996/Vertical-Pathway-Inhibition-Overcomes-Adaptive[43] [43]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9809542/[44] [52]: https://pubmed.ncbi.nlm.nih.gov/35732135/[45] [85]: https://www.nature.com/articles/s41591-024-03362-3[46] [205]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[47] [354]: https://www.researchgate.net/figure/Amplification-of-wild-type-KRAS-associates-with-elevated-KRAS-expression-and-poor_fig1_325403544[48] [173]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[49] [205]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[50] [312]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[51] [312]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[52] [205]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[53] [100]: https://clinicaltrials.gov/study/NCT06585488[54] [101]: https://www.careacross.com/clinical-trials/trial/NCT06585488[55] [173]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[56] [93]: https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne_CDx_Label_Technical_Info.pdf[57] [94]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9633455/[58] [287]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12469631/[59] [288]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7688175/[60] [178]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11799340/[61] [307]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12211309/[62] [351]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6230847/[63] [154]: https://clinicaltrials.gov/study/NCT06096974[64] [155]: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-09245[65] [265]: https://280bio.com/wp-content/uploads/2023/04/2627_AACR-TEB-17231-sized.pdf[66] [196]: https://clinicaltrials.gov/study/NCT06096974[67] [311]: https://delta.larvol.com/Products/?ProductId=af26bbc5-0d00-48f6-81ba-e5b27b4b3df2[68] [208]: http://www.genfleet.com/en/press_release-96[69] [212]: https://www.marketscreener.com/news/genfleet-therapeutics-inc-announces-first-patient-dosed-in-a-phase-i-ii-trial-of-gfh276-treating-ad-ce7d5bdcdb8af12d[70] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[71] [279]: https://www.jons-online.com/articles/germline-testing-molecular-profiling-now-recommended-in-nccn-pancreatic-cancer-guideline[72] [282]: https://www.esmoopen.com/article/S2059-7029(25)01695-3/pdf[73] [314]: https://www.onclive.com/view/the-role-of-dna-rna-in-comprehensive-genomic-profiling[74] [320]: https://www.genomeweb.com/cancer/nccn-updates-pancreatic-cancer-guidelines-recommends-ngs-tumor-profiling[75] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[76] [356]: https://www.nature.com/articles/s41467-022-33718-7[77] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[78] [357]: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1169586/full[79] [100]: https://clinicaltrials.gov/study/NCT06585488[80] [205]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[81] [287]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12469631/[82] [297]: https://www.sciencedirect.com/science/article/pii/S0923753422017215[83] [289]: https://www.nature.com/articles/s41598-023-30131-y[84] [291]: https://pmc.ncbi.nlm.nih.gov/articles/PMC10754382/[85] [287]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12469631/[86] [288]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7688175/[87] [292]: https://ouci.dntb.gov.ua/en/works/lD0OrMMl/[88] [357]: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1169586/full[89] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[90] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[91] [356]: https://www.nature.com/articles/s41467-022-33718-7[92] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[93] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[94] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[95] [130]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7594413/[96] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[97] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[98] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[99] [357]: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1169586/full[100] [357]: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1169586/full[101] [222]: https://www.wjgnet.com/1007-9327/tables/v31/i43/111433.htm[102] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[103] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[104] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[105] [357]: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1169586/full[106] [357]: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1169586/full[107] [356]: https://www.nature.com/articles/s41467-022-33718-7[108] [222]: https://www.wjgnet.com/1007-9327/tables/v31/i43/111433.htm[109] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[110] [356]: https://www.nature.com/articles/s41467-022-33718-7[111] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[112] [117]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[113] [128]: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2828753[114] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[115] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[116] [357]: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1169586/full[117] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[118] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[119] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[120] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[121] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[122] [100]: https://clinicaltrials.gov/study/NCT06585488[123] [101]: https://www.careacross.com/clinical-trials/trial/NCT06585488[124] [204]: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-kras-inhibitor-bgb-53038[125] [204]: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-kras-inhibitor-bgb-53038[126] [266]: https://www.revmed.com/wp-content/uploads/2024/04/AACR2024_6236_FINAL-DRAFT.pdf[127] [182]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11149917/[128] [336]: https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit[129] [338]: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4230[130] [342]: https://www.targetedonc.com/view/daraxonrasib-earns-fda-breakthrough-status-in-pancreatic-cancer[131] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[132] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[133] 1. KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11049385%2F[134] [1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11049385/[135] 2. KRAS G12C Game of Thrones, which direct KRAS inhibitor will ...: https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fabs%2Fpii%2FS0305737220300128[136] [8]: https://www.sciencedirect.com/science/article/abs/pii/S0305737220300128[137] 3. Nucleotide based covalent inhibitors of KRas can only be ...: https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41598-017-03973-6[138] [17]: https://www.nature.com/articles/s41598-017-03973-6[139] 4. Targeting KRAS G12C: from inhibitory mechanism to ... - PMC: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC7669705%2F[140] [19]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7669705/[141] 5. Wild-type RAS signaling is an essential therapeutic target in ... - PMC: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12983336%2F[142] [41]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12983336/[143] 6. Concurrent inhibition of oncogenic and wild-type RAS-GTP ... - Nature: https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41586-024-07205-6[144] [42]: https://www.nature.com/articles/s41586-024-07205-6[145] 7. KRASG12C-independent feedback activation of wild-type RAS ...: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9809542%2F[146] [43]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9809542/[147] 8. KRAS G12C-independent feedback activation of wild-type ...: https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35732135%2F[148] [52]: https://pubmed.ncbi.nlm.nih.gov/35732135/[149] 9. Clinicogenomic landscape of pancreatic adenocarcinoma identifies ...: https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-024-03362-3[150] [85]: https://www.nature.com/articles/s41591-024-03362-3[151] 10. Identification of the Clinical Development Candidate MRTX849, a ...: https%3A%2F%2Fpubs.acs.org%2Fdoi%2F10.1021%2Facs.jmedchem.9b02052[152] [87]: https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02052[153] 11. Page 1 of 110 FoundationOne®CDx Technical Information ...: https%3A%2F%2Finfo.foundationmedicine.com%2Fhubfs%2FFMI%2520Labels%2FFoundationOne_CDx_Label_Technical_Info.pdf[154] [93]: https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne_CDx_Label_Technical_Info.pdf[155] 12. Bioinformatically-expanded next-generation sequencing ...: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9633455%2F[156] [94]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9633455/[157] 13. NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS ...: https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06585488[158] [100]: https://clinicaltrials.gov/study/NCT06585488[159] 14. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone ...: https%3A%2F%2Fwww.careacross.com%2Fclinical-trials%2Ftrial%2FNCT06585488[160] [101]: https://www.careacross.com/clinical-trials/trial/NCT06585488[161] 15. Systemic Therapy for Advanced Pancreatic Cancer in 2025: https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2Ffull%2F10.1111%2Fjgh.70353[162] [117]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[163] 16. KRAS Mutation Status and Outcomes in Metastatic Pancreatic ...: https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamanetworkopen%2Ffullarticle%2F2828753[164] [128]: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2828753[165] 17. KRAS wild-type pancreatic ductal adenocarcinoma - PMC - NIH: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC7594413%2F[166] [130]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7594413/[167] 18. Study Details | NCT06096974 | Pan-RAS Inhibitor YL-17231 in ...: https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06096974[168] [154]: https://clinicaltrials.gov/study/NCT06096974[169] 19. Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid ...: https%3A%2F%2Fwww.cancer.gov%2Fresearch%2Fparticipate%2Fclinical-trials-search%2Fv%3Fid%3DNCI-2023-09245[170] [155]: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-09245[171] 20. Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor ...: https%3A%2F%2Faacrjournals.org%2Fmct%2Farticle%2F24%2F4%2F550%2F754287%2FPan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[172] [173]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[173] 21. Multiomic quantification of the KRAS mutation dosage improves the ...: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11799340%2F[174] [178]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11799340/[175] 22. Translational and Therapeutic Evaluation of RAS-GTP ...: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11149917%2F[176] [182]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11149917/[177] 23. ClinicalTrials.gov: https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06096974[178] [196]: https://clinicaltrials.gov/study/NCT06096974[179] 24. Definition of pan-KRAS inhibitor BGB-53038 - NCI Drug Dictionary - NCI: https%3A%2F%2Fwww.cancer.gov%2Fpublications%2Fdictionaries%2Fcancer-drug%2Fdef%2Fpan-kras-inhibitor-bgb-53038[180] [204]: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-kras-inhibitor-bgb-53038[181] 25. Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification | Molecular Cancer Therapeutics | American Association for Cancer Research: https%3A%2F%2Faacrjournals.org%2Fmct%2Farticle%2F24%2F4%2F550%2F754287%2FPan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[182] [205]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[183] 26. Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard‐of‐Care and Emerging Therapeutic Strategies - Kwok - Journal of Gastroenterology and Hepatology - Wiley Online Library: https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2Ffull%2F10.1111%2Fjgh.70353[184] [207]: https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70353[185] 27. GenFleet Therapeutics Announces First Patient Dosed with GFH276 ...: http%3A%2F%2Fwww.genfleet.com%2Fen%2Fpress_release-96[186] [208]: http://www.genfleet.com/en/press_release-96[187] 28. GenFleet Therapeutics Inc. Announces First Patient Dosed in A ...: https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fgenfleet-therapeutics-inc-announces-first-patient-dosed-in-a-phase-i-ii-trial-of-gfh276-treating-ad-ce7d5bdcdb8af12d[188] [212]: https://www.marketscreener.com/news/genfleet-therapeutics-inc-announces-first-patient-dosed-in-a-phase-i-ii-trial-of-gfh276-treating-ad-ce7d5bdcdb8af12d[189] 29. Pancreatic cancer in 2025: Have we found a solution?: https%3A%2F%2Fwww.wjgnet.com%2F1007-9327%2Ftables%2Fv31%2Fi43%2F111433.htm[190] [222]: https://www.wjgnet.com/1007-9327/tables/v31/i43/111433.htm[191] 30. Biophysical and structural analysis of KRAS switch-II pocket ...: https%3A%2F%2Fwww.jbc.org%2Farticle%2FS0021-9258(25)02181-7%2Ffulltext[192] [244]: https://www.jbc.org/article/S0021-9258(25)02181-7/fulltext[193] 31. Fragment Optimization of Reversible Binding to the Switch II Pocket ...: https%3A%2F%2Fpubs.acs.org%2Fdoi%2F10.1021%2Facs.jmedchem.2c01120[194] [247]: https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01120[195] 32. https%3A%2F%2F280bio.com%2Fwp-content%2Fuploads%2F2023%2F04%2F2627_AACR-TEB-17231-sized.pdf: https%3A%2F%2F280bio.com%2Fwp-content%2Fuploads%2F2023%2F04%2F2627_AACR-TEB-17231-sized.pdf[196] [265]: https://280bio.com/wp-content/uploads/2023/04/2627_AACR-TEB-17231-sized.pdf[197] 33. https%3A%2F%2Fwww.revmed.com%2Fwp-content%2Fuploads%2F2024%2F04%2FAACR2024_6236_FINAL-DRAFT.pdf: https%3A%2F%2Fwww.revmed.com%2Fwp-content%2Fuploads%2F2024%2F04%2FAACR2024_6236_FINAL-DRAFT.pdf[198] [266]: https://www.revmed.com/wp-content/uploads/2024/04/AACR2024_6236_FINAL-DRAFT.pdf[199] 34. Ras Binder Induces a Modified Switch-II Pocket in GTP- and GDP-States - PMC: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC5915340%2F[200] [267]: https://pmc.ncbi.nlm.nih.gov/articles/PMC5915340/[201] 35. Actionable mutations in pancreatic cancer: where targeted therapies are making a difference - PMC: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12666113%2F[202] [268]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12666113/[203] 36. KRASG12C-independent feedback activation of wild-type RAS ...: https%3A%2F%2Fwww.researchgate.net%2Fpublication%2F361445890_KRASG12C-independent_feedback_activation_of_wild-type_RAS_constrains_KRASG12C_inhibitor_efficacy[204] [271]: https://www.researchgate.net/publication/361445890_KRASG12C-independent_feedback_activation_of_wild-type_RAS_constrains_KRASG12C_inhibitor_efficacy[205] 37. Vertical Pathway Inhibition Overcomes Adaptive Feedback ...: https%3A%2F%2Faacrjournals.org%2Fclincancerres%2Farticle%2F26%2F7%2F1633%2F265996%2FVertical-Pathway-Inhibition-Overcomes-Adaptive[206] [272]: https://aacrjournals.org/clincancerres/article/26/7/1633/265996/Vertical-Pathway-Inhibition-Overcomes-Adaptive[207] 38. Germline Testing, Molecular Profiling Now Recommended in NCCN ...: https%3A%2F%2Fwww.jons-online.com%2Farticles%2Fgermline-testing-molecular-profiling-now-recommended-in-nccn-pancreatic-cancer-guideline[208] [279]: https://www.jons-online.com/articles/germline-testing-molecular-profiling-now-recommended-in-nccn-pancreatic-cancer-guideline[209] 39. Pan-Asian adapted ESMO Clinical Practice Guidelines for the ...: https%3A%2F%2Fwww.esmoopen.com%2Farticle%2FS2059-7029(25)01695-3%2Fpdf[210] [282]: https://www.esmoopen.com/article/S2059-7029(25)01695-3/pdf[211] 40. KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid ...: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12469631%2F[212] [287]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12469631/[213] 41. Detection of KRAS mutations in liquid biopsies from metastatic ...: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC7688175%2F[214] [288]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7688175/[215] 42. Efficient and accurate KRAS genotyping using digital PCR ... - Nature: https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41598-023-30131-y[216] [289]: https://www.nature.com/articles/s41598-023-30131-y[217] 43. Comparison of KRAS gene in circulating tumor DNA levels vs ... - PMC: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC10754382%2F[218] [291]: https://pmc.ncbi.nlm.nih.gov/articles/PMC10754382/[219] 44. Identification of a Clinical Cutoff Value for Multiplex KRASG12/G13 ...: https%3A%2F%2Fouci.dntb.gov.ua%2Fen%2Fworks%2FlD0OrMMl%2F[220] [292]: https://ouci.dntb.gov.ua/en/works/lD0OrMMl/[221] 45. ESMO recommendations on the use of circulating tumour DNA ...: https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0923753422017215[222] [297]: https://www.sciencedirect.com/science/article/pii/S0923753422017215[223] 46. Distinct clinical outcomes and biological features of specific KRAS ...: https%3A%2F%2Fwww.cell.com%2Fcancer-cell%2Ffulltext%2FS1535-6108(24)00296-4[224] [305]: https://www.cell.com/cancer-cell/fulltext/S1535-6108(24)00296-4[225] 47. Elevated KRAS protein level is associated with better survival ...: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12211309%2F[226] [307]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12211309/[227] 48. GFH276 / GenFleet Therap: https%3A%2F%2Fdelta.larvol.com%2FProducts%2F%3FProductId%3Daf26bbc5-0d00-48f6-81ba-e5b27b4b3df2[228] [311]: https://delta.larvol.com/Products/?ProductId=af26bbc5-0d00-48f6-81ba-e5b27b4b3df2[229] 49. Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification | Molecular Cancer Therapeutics | American Association for Cancer Research: https%3A%2F%2Faacrjournals.org%2Fmct%2Farticle%2F24%2F4%2F550%2F754287%2FPan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[230] [312]: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display[231] 50. The Role of DNA & RNA in Comprehensive Genomic ...: https%3A%2F%2Fwww.onclive.com%2Fview%2Fthe-role-of-dna-rna-in-comprehensive-genomic-profiling[232] [314]: https://www.onclive.com/view/the-role-of-dna-rna-in-comprehensive-genomic-profiling[233] 51. NCCN Updates Pancreatic Cancer Guidelines ...: https%3A%2F%2Fwww.genomeweb.com%2Fcancer%2Fnccn-updates-pancreatic-cancer-guidelines-recommends-ngs-tumor-profiling[234] [320]: https://www.genomeweb.com/cancer/nccn-updates-pancreatic-cancer-guidelines-recommends-ngs-tumor-profiling[235] 52. Sotorasib shows clinically meaningful activity in KRAS G12C ...: https%3A%2F%2Fwww.mdanderson.org%2Fnewsroom%2Fkras-inhibitor-sotorasib-shows-meaningful-activity-pancreatic-cancer.h00-159545268.html[236] [325]: https://www.mdanderson.org/newsroom/kras-inhibitor-sotorasib-shows-meaningful-activity-pancreatic-cancer.h00-159545268.html[237] 53. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer: https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F36546651%2F[238] [326]: https://pubmed.ncbi.nlm.nih.gov/36546651/[239] 54. Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit ...: https%3A%2F%2Fir.revmed.com%2Fnews-releases%2Fnews-release-details%2Fdaraxonrasib-demonstrates-unprecedented-overall-survival-benefit[240] [336]: https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit[241] 55. Trial in progress: RASolute 302—A phase 3, multicenter, global ...: https%3A%2F%2Fascopubs.org%2Fdoi%2F10.1200%2FJCO.2025.43.16_suppl.TPS4230[242] [338]: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4230[243] 56. Daraxonrasib Earns FDA Breakthrough Status in Pancreatic Cancer: https%3A%2F%2Fwww.targetedonc.com%2Fview%2Fdaraxonrasib-earns-fda-breakthrough-status-in-pancreatic-cancer[244] [342]: https://www.targetedonc.com/view/daraxonrasib-earns-fda-breakthrough-status-in-pancreatic-cancer[245] 57. Increased mutant KRAS gene dosage drives pancreatic cancer ...: https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6230847%2F[246] [351]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6230847/[247] 58. Amplification of wild-type KRAS associates with elevated ...: https%3A%2F%2Fwww.researchgate.net%2Ffigure%2FAmplification-of-wild-type-KRAS-associates-with-elevated-KRAS-expression-and-poor_fig1_325403544[248] [354]: https://www.researchgate.net/figure/Amplification-of-wild-type-KRAS-associates-with-elevated-KRAS-expression-and-poor_fig1_325403544[249] 59. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma | Nature Communications: https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41467-022-33718-7[250] [356]: https://www.nature.com/articles/s41467-022-33718-7[251] 60. Frontiers | Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma: https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Foncology%2Farticles%2F10.3389%2Ffonc.2023.1169586%2Ffull[252] [357]: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1169586/full